ReviewEJNMMI radiopharmacy and chemistry2026
Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.
Review in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Calibration and count rate performance of NaI(Tl) gamma counters for quantifying the activityJournal of applied clinical medical physics · 2026Article
- A Head-to-Head Comparison of Two Antibodies for HER2 Pretargeted PET Imaging via Bioorthogonal Click Chemistry.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Advances in Nuclear Medicine Diagnostics: The Promise of Radiolabeled Dendrimers.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmuno-positron emission tomography (immuno-PET) imaging is emerging as a highly promising technique for the non-invasive diagnosis of a wide range of pathological conditions, particularly in oncology and immunology. This molecular imaging modality enables the visualization, characterization, and quantification of biological processes at a cellular and molecular level. MAIN BODY: Immuno-PET relies mostly on the administration of monoclonal antibodies (mAb) labeled with positron-emitting radionuclides. These antibodies are specifically designed to bind to antigens that are overexpressed on tumor cells or involved in pathological non-neoplastic processes, such as inflammatory or autoimmune diseases. Numerous disease-associated antigens have been identified and are currently being explored as potential molecular targets for immuno-PET, paving the way for more personalized diagnostic and treatment approaches. This technique offers significant potential in the context of theranostic, as it allows for the simultaneous assessment of both diagnostic and therapeutic parameters. It is particularly useful for predicting and monitoring the pharmacokinetics and biodistribution of targeted therapies, thereby helping to optimize therapeutic efficacy while minimizing adverse effects. Among the various radioisotopes available, zirconium-89 (
conclusionIn this review, we aim to provide an overview of the current clinical applications of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.